View:
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------
FORM 8-K
-------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 17, 1997
-----------------------
ALEXION PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-27756 13-3648318
- ---------------------------- ----------- -------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
25 Science Park, New Haven, CT 06511
- ---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (203) 776-1790
-------------------------
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS
On June 17, 1997, Alexion Pharmaceuticals, Inc. issued the press release
filed herewith as Exhibit 99.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(C) EXHIBITS.
99. Press Release dated June 17, 1997.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC.
Date: June 17, 1997 By: /s/ Leonard Bell, M.D.
----------------------
Name: Leonard Bell, M.D.
Title: President, Chief Executive
Officer, Secretary and Treasurer
Exhibit 99
FOR IMMEDIATE RELEASE
Contact: Leonard Bell, M.D. Rhonda Chiger (Investor)
President and CEO Susan Farley (Media)
Alexion Pharmaceuticals Dewe Rogerson Inc.
203/776-1790 212/688-6840
ALEXION ENTERS AGREEMENTS FOR $11.2 MILLION
IN PRIVATE PLACEMENT
New Haven, CT, June 17, 1997 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN)
today announced that it has entered into agreements with institutional investors
to raise $11.2 million in a private placement of 1.45 million shares of common
stock. Robertson, Stephens & Company LLC served as Placement Agent in the
transaction.
"We are extremely pleased by the repeat investment by certain of our existing
institutional shareholders and we welcome the additional institutional investors
to Alexion," said Dr. Leonard Bell, President and Chief Executive Officer.
Proceeds from the private placement will be used to fund the Company's research
and development activities including ongoing and planned clinical studies,
production of clinical trial material, preclinical studies, and for general
corporate purposes. The financing will close upon the effectiveness of the
resale registration statement to be filed by the Company with the Securities and
Exchange Commission in connection with these shares.
Alexion Pharmaceuticals, Inc. was founded in 1992 and is engaged in the
development of selective immunotherapeutic drugs that generally are designed to
inhibit the disease-causing segments of the immune system while preserving the
disease-preventing aspects of the immune system. The Company is developing three
technology platforms: C5 Complement Inhibitors and Apogen T-Cell Therapeutics
which together target severe cardiovascular and autoimmune disorders; and
xenografts for organ transplants.
This news release contains forward looking statements. Such statements are
subject to certain factors which may cause the Alexion's plans to differ or
results to vary from those expected including unexpected preclinical or clinical
results, the need for additional research and testing, delays in manufacturing,
access to capital and funding, delays in development of commercial relationships
and a variety of risks set forth from time to time in the Alexion's filings with
the Securities and Exchange Commission, including but not limited to Alexion's
Annual Report on Form 10-K for the year ended July 31, 1996 and those risks as
discussed in Alexion's Registration Statement (Registration No. 333-19905 filed
April 4, 1997). Alexion undertakes no obligation to publicly release results of
any of these forward-looking statements which may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. The shares of Common Stock have not been registered under
the Securities Act of 1933, as amended, and may not be offered and sold in the
United States absent registration under such Act or an applicable exemption from
registration. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the Common Stock nor shall there be any sale of
these securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any
such state.